Trial Profile
A Phase II Multi-center, Open Label Study of HQP1351 in Chinese Patients of Chronic Myeloid Leukemia With T315I Mutation in Chronic Phase
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Olverembatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Ascentage Pharma
- 02 Nov 2023 According to an Ascendis Pharma media release, as of April 30, 2023, a total of 144 patients were enrolled in this trial.
- 02 Nov 2023 Results presented in the Ascendis Pharma Media Release.
- 02 Nov 2023 According to an Ascendis Pharma media release, data from this trial will be presented at the 2023 ASH Annual Meeting.